PRTN3 and rheumatoid arthritis: The majority of the patients with early RA and with established RA presented a joint-28 disease activity score (DAS28) of moderate/high (53.3% and 76.2%, respectively) and elevated levels of ACPA (66.6% and 57.1%), and they were predominantly under methotrexate (MTX) treatment (46.7% and 76.2%); for some of them, this was in combination with glucocorticoids (GC, 6.7% and 33.3%) or biologics (0% and 7.0%).